Research programme - kinase-inhibiting RNase attenuators - OptiKira

Drug Profile

Research programme - kinase-inhibiting RNase attenuators - OptiKira

Alternative Names: Cell death inhibitors - OptiKira; ERN1 protein inhibitors - OptiKira; Small molecule therapeutics - OptiKira

Latest Information Update: 06 Feb 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator OptiKira
  • Class Small molecules
  • Mechanism of Action Cell death inhibitors; ERN1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Diabetes mellitus; Retinitis pigmentosa
  • Research Amyotrophic lateral sclerosis

Most Recent Events

  • 02 Feb 2015 OptiKira licenses technology from University of California at San Francisco and the University of Washington
  • 02 Feb 2015 OptiKira has patents for kinase-inhibiting RNase attenuators in USA
  • 02 Feb 2015 Early research in Amyotrophic lateral sclerosis in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top